These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 28332360

  • 1. Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA.
    Kim DH, Choi JW, Seo JH, Cho YS, Won SY, Park BK, Jeon HH, Shin SY, Lee CK.
    Yonsei Med J; 2017 May; 58(3):552-556. PubMed ID: 28332360
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine.
    Cai S, Cao J, Yu T, Xia M, Peng J.
    Medicine (Baltimore); 2017 Jun; 96(22):e7021. PubMed ID: 28562554
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine.
    Lo AO, Wong VW, Wong GL, Chan HY, Cheung CM, Chan HL.
    Antivir Ther; 2013 Jun; 18(5):671-9. PubMed ID: 23462214
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H.
    J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
    Pan HY, Pan HY, Song WY, Zheng W, Tong YX, Yang DH, Dai YN, Chen MJ, Wang MS, Huang YC, Zhang JJ, Huang HJ.
    J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
    [Abstract] [Full Text] [Related]

  • 6. Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B.
    Law ST, Lee MK, Li KK, Mok CK.
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):193-8. PubMed ID: 26587867
    [Abstract] [Full Text] [Related]

  • 7. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
    Woo HY, Park JY, Bae SH, Kim CW, Jang JY, Tak WY, Kim DJ, Kim IH, Heo J, Ahn SH.
    Clin Mol Hepatol; 2020 Jul; 26(3):352-363. PubMed ID: 32460460
    [Abstract] [Full Text] [Related]

  • 8. Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels.
    Shi H, Han Z, Liu J, Xue J, Zhang S, Zhu Z, Xia J, Huang M.
    Med Sci Monit; 2017 Nov 02; 23():5230-5236. PubMed ID: 29095799
    [Abstract] [Full Text] [Related]

  • 9. Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: outcome at 2 Years.
    Fung J, Lai CL, Yuen J, Cheng C, Wu R, Wong DK, Seto WK, Hung IF, Yuen MF.
    Hepatology; 2011 Apr 02; 53(4):1148-53. PubMed ID: 21480321
    [Abstract] [Full Text] [Related]

  • 10. Comparison of clinical efficacy and renal safety of telbivudine and entecavir in chronic hepatitis B patients receiving cytotoxic chemotherapy.
    Law ST, Lee MK, Lee AS, Tung Y, Li KK.
    J Dig Dis; 2016 May 02; 17(5):325-33. PubMed ID: 27085094
    [Abstract] [Full Text] [Related]

  • 11. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.
    Su QM, Ye XG.
    World J Gastroenterol; 2012 Nov 21; 18(43):6290-301. PubMed ID: 23180951
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.
    Kim HR, Yim HJ, Kang S, Suh SJ, Kim SY, Hyun JJ, Koo JS, Kim JH, Seo YS, Yeon JE, Lee SW, Byun KS, Um SH.
    Liver Int; 2015 Mar 21; 35(3):860-9. PubMed ID: 24905912
    [Abstract] [Full Text] [Related]

  • 13. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
    Koffi J, Egounlety R, Pradat P, Lebosse F, Si-Ahmed SN, Lussier V, Chevallier P, Bailly F, Zoulim F.
    Eur J Gastroenterol Hepatol; 2014 Feb 21; 26(2):146-54. PubMed ID: 24025974
    [Abstract] [Full Text] [Related]

  • 14. Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification.
    Choi JW, Kim SH, Seo JH, Cho YS, Won SY, Park BK, Jeon HH, Lee YK, Lee CK.
    Yonsei Med J; 2018 May 21; 59(3):383-388. PubMed ID: 29611400
    [Abstract] [Full Text] [Related]

  • 15. Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.
    An J, Lim YS, Kim GA, Han SB, Jeong W, Lee D, Shim JH, Lee HC, Lee YS.
    BMC Gastroenterol; 2017 Jan 19; 17(1):15. PubMed ID: 28103819
    [Abstract] [Full Text] [Related]

  • 16. [Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].
    Ji FZ, Wang L, Yang BH, Zhao JJ, Liu F, Xue Y, Li T.
    Zhonghua Gan Zang Bing Za Zhi; 2012 Apr 19; 20(4):280-4. PubMed ID: 22964149
    [Abstract] [Full Text] [Related]

  • 17. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
    Yue-Meng W, Li YH, Wu HM, Yang J, Xu Y, Yang LH, Yang JH.
    Clin Exp Med; 2017 May 19; 17(2):233-241. PubMed ID: 27094312
    [Abstract] [Full Text] [Related]

  • 18. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.
    Chaung KT, O'Brien C, Ha NB, Nguyen NH, Trinh HN, Nguyen MH.
    J Clin Gastroenterol; 2016 Apr 19; 50(4):338-44. PubMed ID: 26646801
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F, Toyoda J, Katano Y, Sata M, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Kumada H.
    J Gastroenterol Hepatol; 2008 Sep 19; 23(9):1320-6. PubMed ID: 18554238
    [Abstract] [Full Text] [Related]

  • 20. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
    Salpini R, Alteri C, Cento V, Pollicita M, Micheli V, Gubertini G, De Sanctis GM, Visca M, Romano S, Sarrecchia C, Andreoni M, Angelico M, Parruti G, Svicher V, Perno CF.
    J Med Virol; 2013 Jun 19; 85(6):996-1004. PubMed ID: 23588725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.